Saturday 17 October 2026
Export GMAB’s income statement to Excel — free account
Genmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.9%, EPS fell 9.26% and free cash flow fell 7.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
37.00
0.82
−2.17%
Follow GMAB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
21.63 | 20.33 | 19.87 | 13.00 |
+8 more quarters Free account |
P/S ratio |
4.08 | 4.34 | 5.15 | 5.27 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 15.89 | |
P/Operating CF |
330.37 | 5,642.80 | 63.60 | 35.25 | |
P/B ratio |
2.83 | 2.98 | 3.27 | 3.29 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 5.18 | |
EV/Sales |
4.96 | 5.28 | 6.10 | 4.35 | |
EV/EBITDA |
17.57 | 18.07 | 19.98 | 11.27 | |
EV/Operating CF |
22.99 | 22.86 | 19.14 | 12.24 | |
EV/FCF |
(3.23) | (3.24) | (3.73) | 13.12 | |
Quick Ratio |
2.44 | 2.17 | 2.01 | 6.01 | |
Current Ratio |
2.46 | 2.18 | 2.02 | 6.03 | |
Net Debt/EBITDA |
9.06 | 17.64 | 45.05 | (7.15) | |
Debt/Assets |
41.03% | 42.08% | 40.97% | 0.00% | |
Debt/Equity |
0.86 | 0.92 | 0.90 | 0.00 | |
Asset Turnover |
0.44 | 0.41 | 0.39 | 0.56 | |
Operating CF/Net income |
0.17 | 0.06 | 9.71 | 1.34 | |
Capex/Depreciation |
(0.12) | (0.17) | (344.19) | (0.11) | |
Interest Coverage |
2.70 | 1.20 | 0.60 | 12.41 | |
Research and Development Expense of Revenue |
39.74% | 49.11% | 49.72% | 34.93% | |
Selling, General and Administrative Expense of Revenue |
17.75% | 18.53% | 19.66% | 14.48% | |
Intangible Assets out of Total Assets |
0.74 | 0.75 | 0.74 | 0.30 | |
Share Based Compensation of Revenue |
3.20% | 5.47% | 3.40% | 3.33% | |
Graham Net Nets |
(0.22) | (0.24) | (0.22) | 0.17 | |
Graham Number |
16.66 | 16.35 | 18.11 | 22.27 | |
Earnings Yield |
4.62% | 4.92% | 5.03% | 7.69% | |
Free Cash Flow Yield |
(37.67%) | (37.58%) | (31.78%) | 6.29% | |
Revenue per Share |
1.88 | 1.42 | 1.70 | 1.66 | |
Operating CF per Share |
0.08 | 0.00 | 0.48 | 0.87 | |
Capex per Share |
0.00 | (0.01) | (11.63) | 0.00 | |
Free Cash Flow per Share |
0.08 | 0.00 | (11.15) | 0.87 | |
Cash per Share |
2.45 | 2.41 | 2.76 | 5.54 | |
Shareholders Equity per Share |
9.71 | 9.01 | 9.41 | 9.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.71 | 9.01 | 9.41 | 9.34 | |
Free Cash Flow |
48.00 | (2.00) | (6,927.00) | 534.00 | |
Working Capital |
1,661.00 | 1,395.00 | 1,458.00 | 3,730.00 | |
Capital Expenditures |
(3.00) | (5.00) | (7,228.00) | (2.00) | |
Net Current Asset Value |
(3,757.00) | (4,121.00) | (4,141.00) | 3,201.00 | |
EV/EBIT |
19.11 | 19.50 | 21.32 | 11.84 | |
Capex to Sales |
0.00 | 0.01 | 6.83 | 0.00 | |
Price to Operating Income |
15.72 | 16.02 | 17.97 | 14.34 | |
| Other line items | |||||
Average Receivables |
1,139.00 | 915.00 | 1,044.50 | 988.05 | |
Average Inventory |
15.50 | 16.50 | 13.50 | 12.23 | |
Average Assets |
9,489.50 | 9,481.00 | 9,643.50 | 6,433.44 | |
Average Common Equity |
5,629.50 | 5,489.00 | 5,492.00 | 5,228.15 |
Columns are period end dates